Background: Metastatic angiosarcoma to the brain is a rare entity without an established
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and the lack of diagnostic tissue, the patient underwent a left frontal craniotomy for tumor resection.
Neurosurgical Operation and Pathology
At surgery, the tumor was noted to have black coloration with distinct margins and firm consistency. It was easily identified and removed en-block to avoid hemorrhage. Pathologic evaluation was significant for a tumor composed of anastomosing vascular channels lined with malignant endothelial cells. Areas of necrosis, and hemorrhage were also present. The tumor cells were positive for CD31 and CD34 with immunohistochemistry. (Figure 2 ) The CNS tissue matched the lung biopsy tissue and represented metastatic angiosarcoma. Given the propensity of angiosarcomas to originate from the right atrium, his right atrial mass was presumed to be the primary source.
Post-operative Course
The patient regained strength in his right upper extremity post-operatively. The cardiothoracic surgery team was consulted and did not recommend resection of his right atrial appendage mass. He was ultimately discharged to an acute rehabilitation facility on post-operative day 7. Gemcitabine, 
Discussion
We describe a case of a cardiac angiosarcoma with multiple metastasis to the lung, spine, and brain.
Primary and metastatic CNS angiosarcomas are a rare malignancy with an incidence rate less than 1%
1-4 Described risk factors for angiosarcoma include vinyl chloride, irradiation, chemotherapy, arsenic and thorotrast-contrast. 1, [5] [6] [7] [8] In published case reports of angiosarcoma of the CNS, the clinical presentation is often rapid onset of neurologic deficits with intracranial hemorrhage. [9] [10] [11] [12] [13] The propensity of angiosarcomas to hemorrhage is underscored by a report of surgical resection that required 12 units of packed red blood cell and plasma transfusions. 4 Systemic angiosarcomas originate from endothelial cell of arteries, veins, or lymphatic channels. 5, 14 Similarly, primary CNS angiosarcomas originate from the mesenchymal elements of the brain. Figure 2 ).
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with 70% male predominance. 2 Primary sites of disease have included the heart, aorta, femur, placenta, spleen, liver and scalp. [7] [8] [9] 12, 19, [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] The most common primary site of angiosarcomas with CNS metastasis is the right atrium of the heart (35% of reported cases). 8, 9, 12, 13, 28, 30, 35, 40 The most common metastasis sites are the cervical lymph nodes, lung, liver and spleen. 7, 41 In our patient, we suspect that the primary site was the right atrial mass, with metastatic spread to the lung and brain. Gross total resection has been recommended as first-line treatment for both primary and metastatic CNS angiosarcoma given the propensity of these tumors to recur. 15, 30 Adjuvant treatment options include chemotherapy, radiation therapy and local brachytherapy. However, a standardized protocol has not been established. Moreover, a review of 99 cases of angiosarcoma demonstrated that often no treatment for these patients was undertaken. 7 One reason may be because gross total resection is often difficult given the size and multiplicity of these tumors, as well as their propensity to hemorrhage. 13, 42 Secondly, sarcomas are radioresistant. Mean survival following whole brain radiation for CNS sarcomas is 3 months. 13 Stereotactic radiosurgery is also minimally effective for sarcomas. 43, 44 Finally, use of chemotherapy agents such as paclitaxel, gemicitabine, bevacizumab, sorafenib, and docetaxel have been used against angiosarcoma. 42, [45] [46] [47] [48] [49] However, angiosarcomas have been partially resistant to these chemotherapies, with most reported time-to-progression remaining under 12 months and overall survival ranging from 6 to 15 months. 42, [45] [46] [47] [48] [49] These data M A N U S C R I P T
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6 reflect the difficulty in treating angiosarcoma. Regardless, using each of these treatment modalities in combination has been recommended given the tumor's malignant features. 15, 22, 28 Genomic studies of angiosarcoma have been reported. Zhrebker et al reported a case of a 56 year old male with metastatic angiosarcoma who underwent postmortem whole exome sequencing. They discovered the patient had a KDR mutation, a vascular-specific tyrosine kinase receptor, resulting in its overactivation. 50 KDR mutations in angiosarcoma patients has been reported to have a 10%
incidence and the whole exome sequencing study supported the potential clinical efficacy of a KDR inhibitor. 51 Other genomic studies have demonstrated an upregulation of p53, Ras, BRCA, PTEN, and MYC in angiosarcomas. 52, 53 Morphoproteomic studies of angiosarcoma patients demonstrated constitutive activation of (1) the signal transducer and activator of transcription (STAT3) pathway, (2) the ras/Raf kinase/extracellular signal-regulated kinase (ERK) pathway, (3) the hypoxia pathway, (4) the sonic hedgehog pathway, and (5) the mechanistic target of rapamycin (mTOR) pathway. 52, 54 While these studies provide insight into the different oncogenic pathways utilized by angiosarcomas, the multiplicity of these pathways underscore the difficulty in effectively treating these tumors.
Conclusion
CNS angiosarcoma is a rare and aggressive disease that is resistant to chemotherapy and radiation therapy. Genomic studies of angiosarcoma suggest its uses multiple oncogenic pathways to promote its growth. Here, we present a patient with a primary cardiac angiosarcoma and extensive metastatic angiosarcoma with CNS involvement. Our patient underwent surgical resection of his CNS lesion and adjuvant chemotherapy, which is consistent with prior literature recommendations. Our patient remains alive 12 months after craniotomy without local tumor recurrence. 
